SS-31
Mitochondria-targeted tetrapeptide
SS-31, also known as elamipretide in clinical-development literature, is studied for mitochondrial membrane and cardiolipin-associated biology.
Open SS-31 hub →Research comparison
A research-focused comparison of compound identity, research mechanism, evidence maturity and documentation. This page does not provide dosing or medical guidance.
SS-31
SS-31, also known as elamipretide in clinical-development literature, is studied for mitochondrial membrane and cardiolipin-associated biology.
Open SS-31 hub →MOTS-c
MOTS-c is a mitochondrial-derived signaling peptide studied in metabolic, stress-response and skeletal-muscle research.
Open MOTS-c hub →Key distinction
SS-31 is a synthetic mitochondria-targeted tetrapeptide, while MOTS-c is an endogenous mitochondrial-derived signaling peptide.
Research overlap
Both are grouped under mitochondrial research, but they engage different biological questions.
Evidence context
SS-31 has both preclinical and human clinical-development literature; MOTS-c remains more heavily preclinical and translational.
Independent literature
FAQ
No. They have distinct molecular identities and should be researched and documented separately.
Evidence strength depends on the specific research question. Compare the number and quality of human studies, preclinical studies, study design and whether the exact molecular form matches the compound being discussed.
Not automatically. Findings should remain tied to the compound, model, dose, route and endpoint used in the original study.
Use Northern Peptide Collective's COA Verification page and match analytical documentation to the exact product lot where available.